Chronic Myeloid Leukemia News and Research

RSS
Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. According to the American Cancer Society, CML is a type of cancer that starts in blood-forming cells of the bone marrow and then invades the blood. It can spread to the lymph nodes, spleen, liver, and other parts of the body. CML can also change into a fast-growing acute leukemia that invades almost any organ in the body.
MD Anderson professor to receive award for clinical research excellence at AACR meeting

MD Anderson professor to receive award for clinical research excellence at AACR meeting

Hebrew University professor wins 2013 Award for Outstanding Achievement in Chemistry in Cancer Research

Hebrew University professor wins 2013 Award for Outstanding Achievement in Chemistry in Cancer Research

Media outlets examine reaction to India's Supreme Court ruling on Novartis patent case

Media outlets examine reaction to India's Supreme Court ruling on Novartis patent case

Memorial Sloan-Kettering scientist wins Breakthrough Prize in Life Sciences

Memorial Sloan-Kettering scientist wins Breakthrough Prize in Life Sciences

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

EMA adopts positive opinion for Pfizer’s bosutinib conditional approval in the EU

EMA adopts positive opinion for Pfizer’s bosutinib conditional approval in the EU

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

Rochester scientists propose new reason why acute myeloid leukemia is so difficult to cure

Rochester scientists propose new reason why acute myeloid leukemia is so difficult to cure

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

Cancer-associated inflammation boosts ADAR1 enzyme activity

Cancer-associated inflammation boosts ADAR1 enzyme activity

Iclusig gets FDA approval for two rare blood and bone marrow diseases

Iclusig gets FDA approval for two rare blood and bone marrow diseases

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

TKI-resistant human leukemia stem cells are the source of genomic instability

TKI-resistant human leukemia stem cells are the source of genomic instability

Targeting RAD52 protein can block the process by which leukemia stem cells repair themselves

Targeting RAD52 protein can block the process by which leukemia stem cells repair themselves

Ponatinib offers new hope in drug-resistant leukemia

Ponatinib offers new hope in drug-resistant leukemia

Clinical trial shows effectiveness of ponatinib in patients with leukemia and lymphoma

Clinical trial shows effectiveness of ponatinib in patients with leukemia and lymphoma

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

FDA accepts ARIAD’s ponatinib NDA for filing

FDA accepts ARIAD’s ponatinib NDA for filing